, Volume 41, Issue 2, pp 183–190 | Cite as

Glucocorticoid-induced osteonecrosis

  • Robert S. Weinstein


Awareness of the need for prevention of glucocorticoid-induced fractures is growing, but glucocorticoid administration is often overlooked as the most common cause of nontraumatic osteonecrosis. Glucocorticoid-induced osteonecrosis develops in 9–40% of patients receiving long-term therapy although it may also occur with short-term exposure to high doses, after intra-articular injection, and without glucocorticoid-induced osteoporosis. The name, osteonecrosis, is misleading because the primary histopathological lesion is osteocyte apoptosis. Apoptotic osteocytes persist because they are anatomically unavailable for phagocytosis and, with glucocorticoid excess, decreased bone remodeling retards their replacement. Glucocorticoid-induced osteocyte apoptosis, a cumulative and unrepairable defect, uniquely disrupts the mechanosensory function of the osteocyte–lacunar–canalicular system and thus starts the inexorable sequence of events leading to collapse of the femoral head. Current evidence indicates that bisphosphonates may rapidly reduce pain, increase ambulation, and delay joint collapse in patients with osteonecrosis.


Glucocorticoids Osteonecrosis Avascular necrosis Apoptosis Osteoblasts Osteocytes Bisphosphonates 



I am grateful to Drs. Stavros C. Manolagas, Robert L. Jilka, Maria Almeida, and Charles A. O’Brien for their advice and helpful discussions about the adverse skeletal effects of glucocorticoids and for review of the manuscript. This study was supported by VA Merit Review Grants from the Office of Research and Development, Department of Veterans Affairs and the National Institutes of Health (P01-AG13918).


  1. 1.
    E.W. Boland, N.E. Headley, Management of rheumatoid arthritis with smaller (maintenance) doses of cortisone acetate. JAMA 144, 365–372 (1950)CrossRefGoogle Scholar
  2. 2.
    R.H. Freyberg, C.H. Traeger, M. Patterson, W. Squires, C.H. Adams, C. Stevenson, Problems of prolonged cortisone treatment for rheumatoid arthritis. JAMA 147, 1538–1543 (1951)CrossRefGoogle Scholar
  3. 3.
    A.J. Bollet, R. Black, J.J. Bumin, Major undesirable side-effects resulting from prednisolone and prednisone. JAMA 157, 459–463 (1955)CrossRefGoogle Scholar
  4. 4.
    W.G. Heiman, R.H. Freiberger, Avascular necrosis of the femoral and humeral heads after high-dosage corticosteroid therapy. N. Engl. J. Med. 263, 672–675 (1960)CrossRefGoogle Scholar
  5. 5.
    V. Pietrogrande, R. Mastromarino, Osteopathia da prolungato trattmento cortisonico. Ortop. Tramatol. 25, 791–810 (1957)Google Scholar
  6. 6.
    S.M.S. Nasser, P.W. Ewan, Depot corticosteroid treatment for hay fever causing avascular necrosis of both hips. Br. Med. J. 322, 1589–1591 (2010)CrossRefGoogle Scholar
  7. 7.
    C.J. McClean, R.F.J. Lobo, D.J. Brazier, Cataracts, glaucoma, and femoral avascular necrosis caused by topical corticosteroid ointment. Lancet 345, 330 (1995)CrossRefGoogle Scholar
  8. 8.
    T. Kubo, A. Kojima, S. Yamazoe, K. Ueshima, T. Yamamoto, Y. Hirasawa, Osteonecrosis of the femoral head that developed after long-term topical steroid application. J. Orthop. Sci. 6, 92–94 (2001)PubMedCrossRefGoogle Scholar
  9. 9.
    R.S. Weinstein, Clinical practice: glucocorticoid-induced bone disease. N. Engl. J. Med. 365, 62–70 (2011)PubMedCrossRefGoogle Scholar
  10. 10.
    D.E. Fisher, W.H. Bickel, Corticosteroid-induced avascular necrosis. J. Bone Jt. Surg. Am. 53, 859–873 (1971)Google Scholar
  11. 11.
    H.F. Mankin, Nontraumatic necrosis of bone (osteonecrosis). N. Engl. J. Med. 326, 1473–1479 (1992)PubMedCrossRefGoogle Scholar
  12. 12.
    J.D. Kawedia, S.C. Kaste, D. Pei, J.C. Panetta, X. Cai, C. Cheng, G. Neale, S.C. Howard, W.E. Evans, C.-H. Pui, M.V. Rellinh, Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood 117, 2340–2347 (2011)PubMedCrossRefGoogle Scholar
  13. 13.
    J.J. Nash, A.G. Nash, M.E. Leach, D.M. Poetker, Medical malpractice and corticosteroid use. Otolaryngol. Head Neck Surg. 144, 10–15 (2011)PubMedCrossRefGoogle Scholar
  14. 14.
    W. Drescher, G. Schlieper, J. Floege, F. Eitner, Steroid-related osteonecrosis—an update. Nephrol. Dial. Transplant. 26, 1728–2731 (2010)Google Scholar
  15. 15.
    R.A. Adler, J.R. Curtis, K. Saag, R.S. Weinstein, Glucocorticoid-induced osteoporosis, in Osteoporosis, 3rd edn., ed. by R. Marcus, D. Feldman, D.A. Nelsen, C.J. Rosen (Elsevier-Academic Press, San Diego, 2008), pp. 1135–1166CrossRefGoogle Scholar
  16. 16.
    C.C. Cooper, M. Steinbuch, R. Stevenson, R. Miday, N.B. Watts, The epidemiology of osteonecrosis: findings from the GPRD and THIN databases in the UK. Osteoporos. Int. 21, 569–577 (2010)PubMedCrossRefGoogle Scholar
  17. 17.
    D.T. Felson, J.J. Anderson, Across-study evaluation of association between steroid dose and bolus steroids and avascular necrosis of bone. Lancet i, 902–905 (1987)CrossRefGoogle Scholar
  18. 18.
    S. McAvoy, K.S. Baker, D. Mulrooney, A. Blaes, M. Arora, L.J. Burns, N.S. Majhail, Corticosteroid dose as a risk factor for avascular necrosis of the bone after hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 16, 1231–1236 (2010)PubMedCrossRefGoogle Scholar
  19. 19.
    C.N. Chandler, V. Wright, Deleterious effect of intra-articular hydrocortisone. Lancet ii, 661–663 (1958)CrossRefGoogle Scholar
  20. 20.
    G.S. Habib, W. Saliba, M. Nashashibi, Local effects of intra-articular corticosteroids. Clin. Rheumatol. 29, 347–356 (2010)PubMedCrossRefGoogle Scholar
  21. 21.
    T. Yamamoto, R. Schneider, Y. Iwamoto, P.G. Bullough, Rapid destruction of the femoral head after a single intraarticular injection of corticosteroid into the hip joint. J. Rheumatol. 33, 1701–1704 (2006)PubMedGoogle Scholar
  22. 22.
    Y.J. Lee, J.S. Lee, E.H. Kang, Y.-K. Lee, S.-Y. Kim, Y.W. Song, K.-H. Koo, Vascular endothelial growth factor polymorphisms in patients with steroid-induced femoral head osteonecrosis. J. Orthop. Res. (2011). doi: 10.1002/jor.21492
  23. 23.
    H. Russcher, P. Smit, E.L.T. van den Akker, E.F.C. van Rossum, A.O. Brinkman, F.H. de Jong, S.W.J. Lamberts, J.W. Koper, Two polymorphisms in the glucocorticoid receptor gene directly affect glucocorticoid-regulated gene expression. J. Clin. Endocrinol. Metab. 90, 5804–5810 (2005)PubMedCrossRefGoogle Scholar
  24. 24.
    M.S. Cooper, E.H. Rabbitt, P.E. Goddard, W.A. Bartlett, M. Hewison, P.M. Stewart, Osteoblastic 11β-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure. J. Bone Miner. Res. 17, 979–986 (2002)PubMedCrossRefGoogle Scholar
  25. 25.
    D.J. Prockop, Type II collagen and avascular necrosis of the femoral head. N. Engl. J. Med. 352, 2268–2270 (2005)PubMedCrossRefGoogle Scholar
  26. 26.
    N. Han, Z. Yan, C.-a. Guo, F. Shen, J. Liu, Y. Ski, Z. Zhang, Effects of P-glycoprotein on steroid-induced osteonecrosis of the femoral head. Calcif. Tissue Int. 87, 246–253 (2010)PubMedCrossRefGoogle Scholar
  27. 27.
    M. Elmantaser, G. Stewart, D. Young, R. Duncan, B. Gibson, S.F. Ahmed, Skeletal morbidity in children receiving chemotherapy for acute lymphoblastic leukemia. Arch. Dis. Child. 95, 805–809 (2010)PubMedCrossRefGoogle Scholar
  28. 28.
    A.H. Hautmann, S. Elad, A. Lawitschka, H. Greinix, H. Bertz, J. Halter, M. Faraci, L.C. Hofbauer, S. Lee, D. Wolff, E. Holler, Metabolic bone diseases in patients after allogeneic hematopoietic stem cell transplantation: report from the consensus conference on clinical practice in chronic graft-versus-host disease. Transpl. Int. (2011). doi: 10.1111/j.1432-2277.2011.01264.x
  29. 29.
    P. Mehta, M. Nelson, A. Brand, F. Boag, Avascular necrosis in HIV. Rheumatol. Int. (2011). doi: 10.1007/s00296-011-2114-5
  30. 30.
    H.M. Frost, A.R. Villananueva, Human osteoblast activity: III. Effect of cortisone on lamellar osteoblast activity. Henry Ford Hosp. Med. Bull. 9, 97–99 (1961)PubMedGoogle Scholar
  31. 31.
    M. Güven, K. Ünay, C. Bes, O. Poyanli, B. Akman, Hip osteonecrosis in Cushing’s disease treated with bone-preserving procedures. J. Orthop. Sci. (2009). doi: 10.1007/s00776-009-1360-1369
  32. 32.
    M. Zaidi, L. Sun, J. Robinson, I.L. Tourkova, L. Liu, Y. Wang, L.-.L. Zhu, X. Liu, J. Li, Y. Peng, G. Yang, X. Shi, A. Levine, J. Iqbal, B.B. Yaroslavskly, C. Isales, H.C. Blair, ACTH protects against glucocorticoid-induced osteonecrosis of bone. Proc. Natl. Acad. Sci. 107, 8782–8787 (2010)PubMedCrossRefGoogle Scholar
  33. 33.
    R.S. Weinstein, R.L. Jilka, A.M. Parfitt, S.C. Manolagas, Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: potential mechanisms of the deleterious effects on bone. J. Clin. Invest. 102, 274–282 (1998)PubMedCrossRefGoogle Scholar
  34. 34.
    C.A. O’Brien, D. Jia, L.I. Plotkin, T. Bellido, C.C. Powers, S.A. Stewart, S.C. Manolagas, R.S. Weinstein, Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 145, 1835–1841 (2004)PubMedCrossRefGoogle Scholar
  35. 35.
    R.S. Weinstein, J.R. Chen, C.C. Powers, S.A. Stewart, R.D. Landes, T. Bellido, R.L. Jilka, A.M. Parfitt, S.C. Manolagas, Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J. Clin. Invest. 109, 1041–1048 (2002)PubMedGoogle Scholar
  36. 36.
    D. Jia, C.A. O’Brien, S.A. Stewart, S.C. Manolagas, R.S. Weinstein, Glucocorticoids act directly on osteoclasts to increase their lifespan and reduce bone density. Endocrinology 147, 5592–5599 (2006)PubMedCrossRefGoogle Scholar
  37. 37.
    R.S. Weinstein, C. Wan, Q. Liu, Y. Wang, M. Almeida, C.A. O’Brien, J. Thostenson, P.K. Roberson, A.L. Boskey, T.L. Clemens, S.C. Manolagas, Endogenous glucocorticoids decrease angiogenesis, vascularity, hydration, and strength in aged mice. Aging Cell 9, 147–161 (2010)PubMedCrossRefGoogle Scholar
  38. 38.
    P.A. Lotke, M.L. Ecker, Osteonecrosis of the knee. J. Bone Jt. Surg. Am. 70, 470–473 (1988)Google Scholar
  39. 39.
    N.V. Bardakos, R.N. Villar, The ligamentum teres of the adult hip. J. Bone Joint Surg. Br. 91, 8–15 (2009)PubMedGoogle Scholar
  40. 40.
    R.S. Weinstein, R.W. Nicholas, S.C. Manolagas, Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. Endocrinology 85, 2907–2912 (2000)Google Scholar
  41. 41.
    T. Kabata, T. Kubo, T. Matsumoto, M. Nishino, K. Tomita, S. Katsuda, T. Horii, N. Uto, I. Kitajima, Apoptotic cell death in steroid induced osteonecrosis: an experimental study in rabbits. J. Rheumatol. 27, 2166–2177 (2000)PubMedGoogle Scholar
  42. 42.
    A.W. Eberhardt, A. Yeager-Jones, H.C. Blair, Regional trabecular bone matrix degeneration and osteocyte death in femora of glucocorticoid-treated rabbits. Endocrinology 142, 1333–1340 (2001)PubMedCrossRefGoogle Scholar
  43. 43.
    J.D.F. Calder, L. Buttery, P.A. Revell, M. Pearse, J.M. Polak, Apoptosis—a significant cause of bone cell death in osteonecrosis of the femoral head. J. Bone Joint Surg. Br. 86, 1209–1213 (2004)PubMedCrossRefGoogle Scholar
  44. 44.
    J.-Y. Ko, F.-S. Wang, C.-J. Wang, T. Wong, W.-Y. Chou, S.-L. Tseng, Increased Dickkopf-1 expression accelerates bone cell apoptosis in femoral head osteonecrosis. Bone 46, 584–591 (2010)PubMedCrossRefGoogle Scholar
  45. 45.
    Y.-S. Youm, S.-Y. Lee, S.-H. Lee, Apoptosis in the osteonecrosis of the femoral head. Clin. Orthop. Surg. 2, 250–255 (2010)PubMedCrossRefGoogle Scholar
  46. 46.
    M.A. Mont, M.G. Zywiel, D.R. Marker, M.S. McGrath, R.E. Delanois, The natural history of asymptomatic osteonecrosis of the femoral head. J. Bone Jt. Surg. Am. 92, 2165–2170 (2010)CrossRefGoogle Scholar
  47. 47.
    K.-A. Lai, W.-J. Shen, C.-Y. Yang, C.-J. Shao, J.-T. Hsu, R.-M. Lin, The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. J. Bone Jt. Surg. Am. 87, 2155–2159 (2005)CrossRefGoogle Scholar
  48. 48.
    S. Agarwala, S.B. Shah, Ten-year follow-up of avascular necrosis of femoral head treated with alendronate for 3 years. J. Arthroplast. (2011). doi: 10.1016/j.arth.2010.11.010
  49. 49.
    L.I. Plotkin, R.S. Weinstein, A.M. Parfitt, S.C. Manolagas, T. Bellido, Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J. Clin. Invest. 104, 1363–1374 (1999)PubMedCrossRefGoogle Scholar
  50. 50.
    R.S. Weinstein, C.A. O’Brien, H. Zhao, P.K. Roberson, S.C. Manolagas, Osteoprotegerin prevents glucocorticoid-induced osteocyte apoptosis in mice. Endocrinology 152, 3323–3331 (2011)PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Division of Endocrinology and Metabolism, Center for Osteoporosis and Metabolic Bone Diseases, Central Arkansas Veterans Healthcare SystemUniversity of Arkansas for Medical SciencesLittle RockUSA

Personalised recommendations